Literature DB >> 7081035

Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia.

K Nademanee, J Hendrickson, R Kannan, B N Singh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7081035     DOI： 10.1016/0002-8703(82)90556-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  16 in total

Review 1.  Amiodarone: maximising survival benefit with empiric or guided therapy.

Authors:  G Steinbeck; U Dorwarth; E Hoffmann
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 2.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 3.  Programmed stimulation in the evaluation of life-threatening or potentially life-threatening ventricular arrhythmias.

Authors:  C Gottlieb; M E Josephson
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

4.  Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.

Authors:  L M Rodríguez; E B Sternick; J L Smeets; C Timmermans; K den Dulk; G Oreto; H J Wellens
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

Review 5.  A benefit-risk assessment of class III antiarrhythmic agents.

Authors:  Bente Brendorp; Oledyg Pedersen; Christian Torp-Pedersen; Naji Sahebzadah; Lars Køber
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 7.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

8.  Sotalol, hypokalaemia, syncope, and torsade de pointes.

Authors:  J K McKibbin; W A Pocock; J B Barlow; R N Millar; I W Obel
Journal:  Br Heart J       Date:  1984-02

9.  Electrophysiologic testing: predictive of amiodarone efficacy in recurrent sustained ventricular tachycardia?

Authors:  I J Mas; A Massumi; M Harlan; J J Seger; R J Hall
Journal:  Tex Heart Inst J       Date:  1987-12

Review 10.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.